These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26103614)

  • 1. How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae.
    Soran H; Schofield JD; Liu Y; Durrington PN
    Curr Opin Lipidol; 2015 Aug; 26(4):247-56. PubMed ID: 26103614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraoxonase, a cardioprotective enzyme: continuing issues.
    Getz GS; Reardon CA
    Curr Opin Lipidol; 2004 Jun; 15(3):261-7. PubMed ID: 15166781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in paraoxonase-1 activity and atherosclerosis.
    Soran H; Younis NN; Charlton-Menys V; Durrington P
    Curr Opin Lipidol; 2009 Aug; 20(4):265-74. PubMed ID: 19550323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage paraoxonase 1 (PON1) binding sites.
    Efrat M; Aviram M
    Biochem Biophys Res Commun; 2008 Nov; 376(1):105-10. PubMed ID: 18762170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis - a protective role for HDL phospholipids.
    Efrat M; Aviram M
    Adv Exp Med Biol; 2010; 660():153-66. PubMed ID: 20221878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of HDL-bound and free PON1 on copper-induced LDL oxidation.
    Bayrak A; Bayrak T; Bodur E; Kılınç K; Demirpençe E
    Chem Biol Interact; 2016 Sep; 257():141-6. PubMed ID: 27510818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic inflammation, intestine, and paraoxonase-1.
    Vakili L; Navab KD; Shabihkhani M; Pourtabatabaei N; Vazirian S; Barseghian Z; Seyedali S; Hough G
    Adv Exp Med Biol; 2014; 824():83-8. PubMed ID: 25038995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
    Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Paraoxonase--important enzyme of the lipid metabolism and potential ally in the antiatherosclerotic treatment].
    Sapian-Raczkowska B; Rabczyński M; Adamiec R
    Pol Merkur Lekarski; 2010 Nov; 29(173):325-7. PubMed ID: 21268919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dietary lipids on paraoxonase-1 activity and gene expression.
    Ferretti G; Bacchetti T
    Nutr Metab Cardiovasc Dis; 2012 Feb; 22(2):88-94. PubMed ID: 22118836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraoxonase and atherosclerosis-related cardiovascular diseases.
    Chistiakov DA; Melnichenko AA; Orekhov AN; Bobryshev YV
    Biochimie; 2017 Jan; 132():19-27. PubMed ID: 27771368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paraoxonase 1, 2 and 3 in humans.
    Rajkovic MG; Rumora L; Barisic K
    Biochem Med (Zagreb); 2011; 21(2):122-30. PubMed ID: 22135851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
    Rosenblat M; Karry R; Aviram M
    Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraoxonase 1 and homocysteine metabolism.
    Perła-Kaján J; Jakubowski H
    Amino Acids; 2012 Oct; 43(4):1405-17. PubMed ID: 22643843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of protection against oxidative modification of LDL by avian HDL.
    Mackness B; Durrington PN; Mackness MI
    Biochem Biophys Res Commun; 1998 Jun; 247(2):443-6. PubMed ID: 9642147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging.
    Cherki M; Berrougui H; Isabelle M; Cloutier M; Koumbadinga GA; Khalil A
    Exp Gerontol; 2007 Aug; 42(8):815-24. PubMed ID: 17532162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paraoxonase 1 (PON1) and stroke; the dilemma of genetic variation.
    Tajbakhsh A; Rezaee M; Rivandi M; Forouzanfar F; Afzaljavan F; Pasdar A
    Clin Biochem; 2017 Dec; 50(18):1298-1305. PubMed ID: 28779954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action.
    Nguyen SD; Sok DE
    Free Radic Res; 2003 Dec; 37(12):1319-30. PubMed ID: 14753756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of genetic (PON1 polymorphism) and environmental factors, especially physical activity, in antioxidant function of paraoxonase.
    Otocka-Kmiecik A; Orłowska-Majdak M
    Postepy Hig Med Dosw (Online); 2009 Dec; 63():668-77. PubMed ID: 20097953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.